ASCOT is currently trialing the use of two different treatment approaches, called ‘domains’. These are:

  • Antiviral drugs – to stop the virus from multiplying
    • Nafamostat
    • Anticoagulants – blood thinning drugs to reduce the risk of clots
      • Low Molecular Weight Heparin

    Antiviral Drug – to stop the virus from multiplying

    Nafamostat is an agent which may block the entry of SARS-CoV-2 (the virus that causes COVID-19) into human cells. Laboratory studies have shown that nafamostat has a strong effect against SARS-CoV-2. It also has blood thinning properties which may help against the clots in the lungs seen in COVIC-19. Nafamostat has been safely used in humans for other conditions such as pancreatitis (an inflamed pancreas).

    Anticoagulants – to reduce the risk of clots

    Currently, all patients who are admitted to hospital with pneumonia, including COVID-19 receive a blood-thinning medication to prevent the development of blood clots in veins and in the lungs. The usual care is to give a low dose (prophylactic dose) of the anticoagulant medication to prevent these blood clots. However, there is a high risk of blood clots amongst COVID-19 patients, and therefore, giving a higher dose of a blood-thinning medication may reduce the risk of clots.
    This study will be evaluating different doses of an anticoagulant called low molecular weight heparin.